Welcome to our dedicated page for Brandes International ETF news (Ticker: BINV), a resource for investors and traders seeking the latest updates and insights on Brandes International ETF stock.
Track all official updates and market developments for Brandes International ETF (BINV) through this dedicated news hub. As a value-focused exchange-traded fund targeting global equities, BINV provides investors with exposure to carefully selected international opportunities. This page consolidates press releases, regulatory filings, and strategic announcements to help stakeholders monitor portfolio adjustments and market positioning.
Key resources include: Quarterly earnings commentary, portfolio rebalancing notices, and management insights about international value investing. Investors can access filings detailing expense ratios, asset allocation changes, and dividend distributions alongside analysis of emerging market trends impacting the fund.
Bookmark this page for timely updates on BINV's performance relative to international benchmarks and competitor ETFs. Subscribers receive alerts when new SEC filings or material events are published, ensuring informed monitoring of this international investment vehicle.
BioInvent International AB (Nasdaq: BINV) recently highlighted significant advancements in its clinical pipeline during the R&D Day. Key updates include three complete responses for lead drug candidate BI-1206 in non-Hodgkin's lymphoma, with two responses lasting over two years, and successful recruitment in Phase 1/2 trials for BI-1808 and BI-1607. Furthermore, interim results show favorable tolerability for BI-1808 in combination with Keytruda, while BI-1607's IND application has been approved by the FDA, allowing for a trial extension to U.S. centers. The company emphasizes its commitment to transforming cancer therapy.
BioInvent International held an Extraordinary General Meeting on July 12, 2022, where it elected Natalie Berner and Nanna Lüneborg as new Board members. The Board will increase by two members, with annual fees for incoming members continuing as resolved by the previous Annual General Meeting. The fees will be paid on a pro-rata basis according to the duration of their service. The minutes of the meeting will be accessible on the company's website. BioInvent focuses on developing immuno-modulatory antibodies for cancer therapies, with several ongoing clinical trials.
Transgene and BioInvent International AB (BINV) have announced a clinical trial collaboration with MSD to evaluate the oncolytic virus BT-001 in combination with KEYTRUDA® in a Phase I/IIa trial for solid tumors. MSD will supply pembrolizumab for this ongoing trial (NCT04725331), which aims to enhance anti-tumor immune responses. This partnership validates BioInvent's clinical pipeline, which includes three candidates across four trials. The trial is being conducted in Europe and has also been authorized in the US.
Transgene and BioInvent International AB (BINV) have announced positive safety data from the ongoing Phase I/IIa trial of BT-001, an oncolytic virus treatment for solid tumors like melanoma. The initial results show BT-001 is well-tolerated, with signs of anti-tumor activity. Key findings include detectable viral presence within tumors, supporting its treatment mechanism. The trial will continue with 18 patients, and the Safety Review Committee has approved dose escalation. The next phase will test BT-001 in combination with pembrolizumab.
Exelixis has announced a strategic partnership with BioInvent to develop novel antibodies aimed at cancer immunotherapy. This collaboration involves an upfront payment of $25 million from Exelixis for rights to select three targets utilizing BioInvent's advanced screening platform. Exelixis plans to leverage its expertise in antibody engineering to advance these therapies and is focused on expanding its biotherapeutics pipeline. The partnership aims to enhance both companies' capabilities in oncology therapeutics.
